- New insights on disease mechanisms and etiologies.
- The latest findings from clinical trials.
- Innovative outlooks on therapy and prevention.
- Advances in diagnostic markers.
- Successful strategies to enhance collaboration between academia and industry.
- A great opportunity to interact with peers and experts in neurodegenerative diseases.
Meet GCT representative
Jeffrey Apter, MD